• Ocular or periocular infections
• Active intraocular inflammation
• Hypersensitivity

• The SUSVIMO implant and/or implant-related procedures have been associated with endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, and conjunctival blebs. Patients should be instructed to report any signs or symptoms that could be associated with these events without delay. Additional surgical and/or medical management may be required
• Vitreous hemorrhage: Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. Vitrectomy may be needed
• Postoperative decrease in visual acuity: A decrease in visual acuity usually occurs over the first 2 postoperative months

The most common adverse reactions (≥10%) were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, conjunctival disorder, cataract, and vitreous hemorrhage.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in the full SUSVIMO Prescribing Information, including BOXED WARNING.

REFERENCES: 1. SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2025.